Second-Line Brigatinib for ALK/ROS1-Rearranged NSCLC

Описание к видео Second-Line Brigatinib for ALK/ROS1-Rearranged NSCLC

Panelists Suresh S. Ramalingam, MD; Marina Garassino, MD; Benjamin Besse, MD, PhD; and Giorgio Scagliotti, MD, PhD, discuss the FDA approval of brigatinib as a second-line treatment for ALK/ROS1-translocated metastatic non–small lung cancer, as well as other promising agents.

Комментарии

Информация по комментариям в разработке